Rivia Strengthens Advisory Board with Appointment of Dr. Rich Christie to Accelerate Global Expansion in Clinical Trial Technology

Rivia Strengthens Advisory Board with Appointment of Dr. Rich Christie to Accelerate Global Expansion in Clinical Trial Technology

Zurich, Switzerland – 19 Sep 2025 – Rivia, the clinical trial intelligence company, today announced the appointment of Dr. Rich Christie, MD, PhD, as Strategic Advisor. This addition reflects Rivia’s commitment to scaling its global presence and advancing integrated clinical trial technology solutions for biopharma sponsors worldwide.

Dr. Christie brings over 25 years of experience at the intersection of clinical development, data science, and technology innovation. He has held senior R&D roles at Roche and Johnson & Johnson, and served as Chief Medical Officer at AiCure, where he helped pioneer the use of AI to transform clinical research.

“Rich’s unique combination of medical, strategic, and technology expertise makes him an ideal advisor as Rivia enters its next phase of growth,” said Erik Scalfaro, CEO and co-founder of Rivia. “His insight into scalable, tech-enabled trial decision will help us broaden our impact and accelerate our mission to become the clinical trial intelligence backbone for biotechs globally.”

Dr. Christie will work closely with Rivia’s leadership team to guide product strategy, market expansion, and partnerships with leading biotech sponsors.

“I am excited to join Rivia at this pivotal moment,” said Dr. Christie. “Rivia’s approach is reshaping how Biotechs make strategic decisions throughout clinical development. I look forward to helping the team expand their global footprint and bring these innovations to biotechs developing transformative therapies.”

About Rivia
Rivia is building the clinical trial intelligence platform that unifies data from across sources in real-time, from EDC, labs, imaging, EDC, and more, into trial workflows and strategic decisions. By combining zero-fault reliability with advanced analytics, Rivia empowers biotechs to accelerate development and deliver life-changing therapies.